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It has been suggested that changes in TNFc serum levels,
among other things, may be involved in certain symptoms
observed in long-term hemodialysis (HD) patients [1—4]. Re-
cently Schindler et al [5] showed that contact of peripheral
blood mononuclear cells (PBMC) with different dialysis mem-
branes, or addition of complement factors to PBMC, caused
transcription of mRNA for TNFa but not its synthesis. Herblin
et al [61 reported that plasma of HD patients contained in-
creased levels of TNFa that were not related to the type of
dialysis membrane or to the dialysis procedure.
Recently, Peetre et al [7] showed that both plasma and urine
of HD patients contain particularly high levels of TNFa binding
protein (TNF-BP). It was found that TNF-BP bind TNFa with
high affinity and specificity, thus interfering with its binding to
its cell receptor and inhibiting its cytotoxic activity [8—10]. The
presence of TNF-BP in a particular sample may interfere with
immunoassays for TNFs, since it may reduce the binding
affinity of the antibody to TNFa or even effectively prevent
such binding. In a non-competitive assay such as a "sandwich
enzyme assay", prior binding of TNFa to TNF-BP will pre-
vent, or markedly reduce its binding to the anti-TNF antibody,
resulting in apparent zero, or low levels of TNFa in the sample.
In a competitive assay, however, such as RIA or fluoroimmu-
noassay (FIA), binding of the labeled antigen to TNF-BP will
reduce its binding to the antibody, resulting in a low measured
value, and thus a correspondly high calculated value for the
concentration of TNFa. Obviously, this latter value is not a true
reflection of the TNFa content of the sample, but rather of the
extent to which labeled TNFa is bound by TNF-BP.
In this report we demonstrate that the interference by
TNF-BP with competitive immunoassays for TNFa in urine
and plasma of HD patients leads to false high levels. By using a
modified competitive assay or a "sandwich enzyme" immu-
noassay, we demonstrate that plasma and urine of HD patients
do not contain elevated concentrations of TNFa.
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Methods
Patients
All patients were long-term hemodialysis (HD) patients un-
dergoing three to four hours of maintenance three times weekly.
Dialysis was performed using artificial kidneys equipped with
regenerated cellulose cuprophane capillary membranes.
Sample collection
Urine. Pooled urine from five HD patients was extensively
dialyzed against 0.15 M sodium chloride and then concentrated
20-fold with an Amicon filter using a PM1O membrane. The pH
was adjusted to 7.7 by addition of concentrated Tris buffer to a
final concentration of 50 m'vi Tris. NaN3 was added to a final
concentration of 0.5 g/liter. The urine (referred to as "HD
urine") was stored in small aliquots at —70°C.
Plasma. A blood sample (10 ml) from each patient was
collected in a heparinized tube (10 U/ml of blood) from the
arterial site of an arteriovenous fistula before and after three
hours of dialysis. The blood was centrifuged and the plasma
was stored in small aliquots at —70°C.
Materials
r-TNFa was from Amgen Biologicals, (California, USA)
Anti-TNFa monoclonal antibodies 2 and 3 were provided by
Drs. De Groote and Baudrihaye of Medgenix (Fleurus, Bel-
gium). Anti-TNFa monoclonal 1 and polyclonal serum (rabbit)
were provided by Prof. D. Wallach (Rehovot, Israel). Eu-
EDTA chelate was from Wallac Oy (Finland). Anti-mouse and
anti-rabbit immunoglobulins were from Dakopatts (Copen-
hagen, Denmark). Phosphatase substrate was from Sigma (St.
Louis, Missouri, USA).
Labeling of r-TNFa with europium
r-TNFa (0.25 mg/mI) was dialyzed overnight at 4°C against 50
mM carbonate buffer pH 9.8. Eu-chelate was added in a molar
excess of 200 and the mixture incubated overnight at 4°C.
Excess of Eu-chelate was then removed by intensive dialysis
against 0.1 M Tris buffer pH 7.8. The labeled TNFa was
stabilized by the addition of BSA 0.1%.
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Fig. 1. Comparison offluoroimmunoassays FFIA and SFIA for determination of TNFa in "HD urine" sample. Standard curves (A) and dilution
profiles (B) of pooled "HD urine", obtained by FFIA (0) and by SFIA (•), using antibody I, as described in Methods. Values are corrected for
nonspecific binding. B/B0 represents the ratio between the measured and the maximal (100%) binding of Eu-TNFa to the antibody. TNFa
concentration in "HD urine", when calculated according to the FFIA curves is 25 ng/ml, while according to the curves obtained with SFIA it is
zero.
Immunoassays for TNFa
TNFa measurements were obtained using a commercial test
kit (BIOKINE TNF, T-cell Sciences, Cambridge, Massachu-
setts, USA), which uses two monoclonal antibodies in a sand-
wich enzyme immunoassay (sensitivity 10 pg/ml).
Fast fluoroiminunoassay (FFIA). This is a solid-phase com-
petition fluoroimmunoassay, requiring only one incubation
step. It is based on competition between Eu-labeled r-TNFa
(Eu-TNFa) and sample TNFa for binding to an anti-TNFa
antibody. A second antibody, (anti-mouse or anti-rabbit IgG), is
bound to the microtiter well and binds the Eu-labeled or
unlabeled IgG-TNFa complex, resulting in rapid and complete
separation of free and antibody-bound antigen. The procedure
is essentially the same as RIA, except that TNFa is labeled with
Eu, and fluorescence is measured instead of radioactivity.
Three monoclonal anti-TNFa antibodies and one polyclonal
antibody (rabbit) were tested. Plasma or urine samples (50 pi),
10 nglml Eu-TNFa (50 jil), and an anti-TNFs antibody (100 s1),
were incubated in the coated microtiter wells for 21/2 hours at
room temperature. After washing of the microtiter wells to
remove any free components, Eu was dissociated from the solid
phase by the addition of an enhancement solution (200 1d)
(Delfia-Wallac Oy Turku, Finland), which produces a soluble
fluorescent Eu chelate complex. A time-resolved fluorometer
(Delfia) was used to measure the fluorescence in each well. The
measured fluorescence is inversely proportional to the concen-
tration of TNFa in the sample.
Since preincubation was found to increase the sensitivity of
the assay by tenfold, in some cases the antibody was preincu-
bated with the sample or standard for eight hours prior to the
addition of Eu-TNFa. The assay procedure was then continued
as described above.
Sequentialfluoroimmunoassay (SFIA). This is a simple mod-
ification of the FFIA, involving an additional incubation step.
Anti-TNFa antibody is incubated with 50 d of unlabeled
sample or standard in microtiter wells coated with anti-mouse
or anti-rabbit IgG antibodies. After two hours the wells are
washed to remove unbound antibody and sample components
(including TNF-BP). Eu-TNFa is then added to the wells for a
further incubation (2 hrs) after which the assay proceeds as in
FFIA. This simple modification prevents binding of Eu-TNFa
to any TNF-BP that may be present in the sample, and the
results therefore reflect the binding of TNFa to the antibody
only.
All assays were conducted in duplicate. Fluorescence values
were corrected for non-specific binding of Eu-TNFa, which
was <8%.
Recovery of TNFa
"Spiked" standard reference samples were prepared by the
addition of r-TNFa at known concentrations to HD urine.
TNFa was then measured using either SFIA or the BIOKINE
sandwich assay. Percentage of TNFa "recovery" was calcu-
lated as:
(measured TNFa) — (baseline TNFa):
(amount of TNFa added) x 100.
Results
Determination of TNFa in "HD urine"
Sandwich enzyme immunoassays for TNFa. TNFa level in
the "HD urine" sample was measured using a sandwich en-
zyme immunoassay, employing two monoclonal antibodies
(BIOKINE). The level of TNFa was found to be below the limit
of detection, that is, less than 10 pglml, similar to values
obtained from urine or healthy subjects.
Fast fluoroimmunoassay (FFIA)for TNFa. A standard curve
and the dilution profile for TNFa in the "HD urine" sample,
obtained by FFIA, are shown in Figure 1. The dilution profiles
of this urine sample, as obtained by FFIA with the four different
antibodies, are shown in Figure 2. The ratio B/B0 represents the
measured binding of Eu-TNFa to the antibody as a fraction of
its maximal (100%) binding: Thus, a ratio of 1 (that is, when B
= B0) means that no TNFa is present in the sample. As shown
in Figures 1 and 2, the results of the FFIA appear to indicate
that the "HD urine" sample contained high amounts of TNFr.
The TNFa concentrations calculated from standard curves
obtained with antibodies 3, 1, PCN and 2 (not shown), were 12,
25, 35 and 45 ng/ml, respectively. Thus the TNFa concentra-
tions in the same urine sample as measured with the different
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Fig. 2. Dilution profiles of pooled HD urine obtained with FFJA with
four different antibodies. TNFa concentrations calculated from the
corresponding standard curves (not shown) were 12, 25, 35 and 45 ng/ml
for antibodies 3 (•), 1 (•), PCN (0) and 2 (•), respectively.
four antibodies are not identical, and all are in strong contrast to
the results of the sandwich enzyme assay.
As shown in Figure 1A, the standard curve obtained by SFIA
does not differ significantly from that obtained with FFIA. In
contrast, the amount of binding (B) of Eu-TNFa with all of the
tested antibodies at all dilutions was 100% (Fig. 1B), indicating
zero concentration of TNFa, which was in agreement with the
results of the sandwich enzyme assay. Since in the SFIA any
TNF-BP that might be present in the "HD urine" sample was
washed away together with other unbound sample components
before Eu-TNFa was added to the reaction mixture, the results
of this assay may be taken as a true reflection of TNFs
concentration in the sample, whereas the results of the FFIA
most probably reflect the extent to which Eu-TNFa is bound by
TNF-BP.
Recovery of TNFa.Quantitative recovery studies were con-
ducted to establish the inhibition of "HD urine" of the binding
of r-TNFa to the different anti-TNFa antibodies, We employed
both the SFIA procedure and BIOKINE sandwich enzyme
assay. Figure 3 presents the standard curves obtained for
r-TNFa, two hours after its addition to 50 d of either buffer
solution or "RD urine" sample, in the presence of monoclonal
antibodies 3 (Fig. 3A) and 2 (Fig. 3B). For both antibodies, as
well as for antibody 1 and PCN (not shown) the calculated
recovery percentage was low, ranging from 4% for antibody 2 to
50% for antibodies 1 and 3. These results indicate the presence
in the "HD urine" sample of a factor, TNF-BP, that prevents or
diminishes the recovery of free r-TNFa by binding to the
r-TNFs added to the sample. In contrast, TNFa recovery using
the same monoclonal antibodies in concentrated urine and
serum samples from healthy subjects (not shown), range be-
tween 95 and 110%.
Poor quantitative recovery of TNFa from "HD urine" sam-
ples was also observed with the BIOKINE sandwich enzyme
assay, as shown in Table 1. These results are in line with the
company's claim that the assay is specific for biologically active
Table 1. Analytical recovery of TNFa from HD urine samples using
a commercial sandwich enzyme assay (BIOKINE)
TNFa added 0 19 64 212.5 460
TNFa recovered 0 12 50 130 110
A total of 25 .rl of HD urine was incubated for two hours at room
temperature with 25 d of standard TNFa solution prior to assay.
Results are expressed in pg/mI.
TNFx. These results demonstrate how various types of immu-
noassays for TNF are affected differently by the presence of
TNF-BP in a sample.
Alteration of preincubation time in FFJA
We have shown that FFIA for TNFa in "HD urine" yields
misleading results because of interference by TNF-BP. The
unsuitability of conventional competitive RIA or FIA for mea-
surement of TNFa is further underlined by the effect of the
preincubation time (preceding the addition of labeled TNFa).
Prolonged preincubation of the test solution with the anti-TNFa
antibody prior to the addition of Eu-TNF to the reaction
mixture markedly increases the sensitivity of the assay, as
shown for standard TNFa solutions in Figure 4 and Table 2.
However, as can be seen from Table 2, such preincubation did
not affect the values of BIB0 in the "HD urine" sample. This
latter finding is not unexpected, since—as demonstrated
above—the B values obtained here by FFIA do not represent
TNFa levels, and therefore should not be influenced by the
longer incubation. This experiment is simple to perform with
commercial RIA kits, and serves to confirm our contention that
the results obtained by one-step competitive immunoassays do
not always reflect TNFa levels in the tested samples.
Determination of TNFa in plasma of HD patients
Plasma from patients was obtained at the beginning and at the
end of a dialysis session. Samples were assayed for TNFa, as
described for "HD urine". With the sandwich enzyme assay
(13 samples), TNFa levels both in predialysis and in postdial-
ysis samples were all below the sensitivity limits of the assay
<10 pg/mI), and were similar to the results obtained in healthy
controls. Use of the two competition assays, FFIA and SFIA,
yielded results similar to those obtained with these assays for
"RD urine" sample, as shown in Table 3. With FFIA, B/B0 for
all plasma samples (both pre- and post-dialysis) was smaller
than 1, as compared with an average B/B0 value of 1.0 for
plasma from healthy controls (not shown). As with the "HD
urine", these results appeared to indicate elevated concentra-
tions of TNFa in the plasma of HD patients; in this case too,
however, the results were misleading. When the same samples
were tested with the SFIA procedure, the average value of BIB0
was 1.04 (indicating zero concentration of TNFa), in agreement
with the results obtained using the sandwich enzyme assay.
Thus, the results obtained by means of FFIA are a reflection not
of the amount of TNFa present in the plasma sample, but of the
extent to which labeled TNFa in the plasma is bound by
TNF-BP.
Discussion
This study demonstrates that when TNFa binding proteins
are present in urine and plasma samples tested for TNFa, they
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Fig. 3. Recovery of TNFa from "lID urine" sample. Various dilutions of TNFa were added to 50 il of "HD urine", incubated for 2 hours at
room temperature, and TNFi was assessed by SFIA as described in Methods. Values obtained for "HD urine" (0) are compared to those obtained
when the same dilutions of TNFa were added to assay buffer (I). Results obtained with monoclonal antibody 3 (A) and antibody 2 (B) are shown.
Recovery percentage was calculated as described in Methods.
Table 2. Effects of preincubation: Comparison between standard TNFa solutions and HD urine dilutions
TNFa concentration
pg/mi
Incubation time B/BQ Sample volumei Incubation0 hr ime B/B08 hr0 hr 8 hr
26
53
156
312
625
1250
2500
5000
12500
50000
— 1.0
— 0.95
— 0.92
— 0.84
1.0 0.68
0.94 0.45
0.85 0.27
0.6 0.15
0.43 —
0.14 —.
1.50
3.1
6.25
12.5
25
50
0.75
0.60
0.46
0.33
0.25
0.18
0.79
0.66
0.51
0.42
0.26
0.21
Standard TNF dilutions or HD urine sample dilutions were incubated with antibody 2 at room temperature for 0 or 8 hours prior to the addition
of Eu-TNFa to the reaction mixture. Values are expressed as BIB0 (Results).
interfere when competitive assays for TNFa such as RIA and
FIA are used, giving rise to false positive results. TNF-BP was
recently purified to homogeneity from urine of HD patients,
from the urine of healthy subjects and the urine of untreated
febrile patients as well. Recently, two TNF-BP isolated from
urine of healthy subjects have been identified as soluble recep-
tors of TNFa [11—131. In preliminary studies we detected high
levels of TNFa soluble receptors in urine and plasma of HD
patients (unpublished results), which most probably account for
the high TNF-BP activity detected in these samples. TNF-BP
binds TNFa with high specificity and high affinity. TNF-BP, by
competing with the TNFi receptor for TNFx, inhibits the
cytotoxic effect of TNFa on L929 cells [7—10]. We found that
TNF-BP also competes with the TNFa antibody for binding to
TNFa. Three different monoclonal anti-TNFa antibodies and a
polyclonal serum were used in this study. With all of them,
binding of TNFa was prevented to various extents by the
presence of TNF-BP in the samples. It follows that none of the
antibodies available to us (including the two monoclonal anti-
bodies used in the BIOKINE kit) bind complexed TNFa with
the same affinity as they bind free TNF.
The results of this study demonstrate that the most suitable
assay for determination of free TNFa is a sandwich enzyme
assay, since it does not give false positive results due to the
presence of TNF-BP. However, if the only available assay is a
competitive one such as RIA or FIA, our study shows how a
simple modification in the assay procedure, that is, the addition
of a second incubation step, makes it possible to distinguish
between the contributions of TNFa and of TNF-BP to the
assay.
TNF, ng/mI TNF, ng/mI
1.0
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Fig. 4. Effect of preincubation on the sensitivity of the FFIA, Standard
dilutions (0) were incubated with anti-TNFa monoclonal antibody 2 for
8 hours at room temperature prior to the addition of Eu-TNF to the
mixture. Eu-TNFa (•) was added at the same time as the anti-TNFa
antibody. In both cases the procedure was continued as described in
Methods. Preincubation increased assay sensitivity by 10-fold.
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Table 3. TNFa in plasma of HD patients during hemodialysis session: Comparison between FFIA, SFIA and BIOKINE assays
Patient
FFIA B/B0 SFIA B/B0 BIOKINE A 490
Before End of Before End of Before End of
no. dialysis dialysis dialysis dialysis dialysis dialysis
1 0.69 0.72 1.01 1,09 0,005 0.005
2 0.79 0.81 1.03 1.09 0.006 0.013
3 0.70 0.57 1.04 1.15 0.004 0.000
4 0.81 0.89 1.0 — 0.007 0.004
5 0.68 0.71 1.0 — 0.001 0.004
6 0.70 0.73 1.01 0.97 0.003 0.005
7 0.46 0.51 1.01 1.04 0.006 0.006
8 0.40 0.40 1.02 1.08 0.005 0.010
Results of FFIA and SFIA are expressed as B/B0 (Methods) (B/B0 = 1 corresponds to zero concentration of TNFa). Results of BIOKINE assay
are expressed as absorbance at 490 nm. The detection limit is 10 pg/mI corresponding to A490 of 0.020. Thus TNFa levels in all samples are <10
pg/mi.
Using both sandwich enzyme assays and the modified com-
petitive assays, we found that the plasma of HD patients did not
contain higher TNFa levels than that of healthy subjects. High
levels of TNFa reported in the literature may reflect elevated
concentrations of TNF-BP rather than authentic high values of
TNFa. The finding of elevated plasma levels of TNF-BP in HD
patients suggests that if TNFcs is produced by PBMC during
dialysis treatment, it is readily neutralized and made ineffective
by the binding protein. It cannot, therefore, be ruled out that
TNFa is produced during dialysis treatment, but is not detect-
able by the six antibodies employed here.
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